[Music] You are not crazy. Well, let's start by saying that this is a life. Maybe not completely, but at least partially.And for that, I would talk about myself in the beginning. Sometimes I question if I'm crazy. More like I always question if I'm crazy.The reasons deferred over time. I used to question if I'm crazy because I fear mannequins. Then I started to question if I'm crazy because I'm scared of aliens abducting me, putting me in a small room where I suffocate when no one noticing or because I just ...

[Musique] Février 1971, je m'incarne dans ce monde. En route pour une aventure terrestre qui prendra fin le moment venu, n'est-ce pas. Une vie à ce jour remplie de moues expériences diverses et variées, certaines plus lourdes que d'autres en émotion.Rien d'extraordinaire mais on dirait. Mars 1976, je suis une petite fille de 5 ans. Ma mère quitte ce monde et mon père me place chez une tente le temps de l'enterrement.De mois de mois interminable. Et oui, un cousin a jugé de bon de me faire explorer un monde ...

Hello everyone. A very good morning to you all. I'm Anu Suraj. I'm a trauma informed therapist and I'm an advocate for child rights and safety and I'm also a child right and safety educator for the past 13 years. Today I would like you all to reflect on something. I would like to put a question forward. What if every child in this world was given a chance to speak their truth? How will the world look like? Imagine yourself as a child trapped in silence, unable to speak out about the abuse that has been sile ...

Clear Regulatory Path to Clinical Trials for Intranasal PTSD Therapy Targeting Multi-Billion-Dollar MarketSARASOTA, FL, May 14, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has entered into an agreement with Frontage Laboratories, a global full-service CRO (contract research organization), for a Food and Drug Administration (FDA) requested 7 ...

COMPASS Pathways (CMPS) Q1 2025 Earnings Call May 08, 2025 08:00 AM ET Company Participants Steve Schultz - Senior Vice President, Investor RelationsKabir Nath - Chief Executive OfficerTeri Loxam - CFO, Principal Financial Officer & Principal Accounting OfficerGuy Goodwin - Chief Medical OfficerPaul Matteis - Managing Director, Head of Therapeutics ResearchCharles Duncan - Managing DirectorSteve Levine - Chief Patient OfficerSumant Kulkarni - Managing DirectorPatrick Trucchio - Managing Director Conference ...

Core Insights - Oragenics, Inc. has submitted its Investigator's Brochure (IB) application for the Phase II clinical trial of ONP-002, a novel intranasal neurosteroid aimed at treating mild traumatic brain injury (mTBI) [1][5] - The Phase II study will assess the feasibility, safety, tolerability, and pharmacokinetics of ONP-002 in mTBI patients, with a focus on cognitive and visual motor testing [2][6] Company Overview - Oragenics is a biotechnology company focused on developing nasal delivery systems for pharmaceutical treatments in neurology and infectious diseases, including therapies for mTBI and Niemann Pick Disease Type C [7] Clinical Trial Details - The Phase II trial is randomized, double-blind, and placebo-controlled, enrolling 40 participants, with 20 receiving ONP-002 and 20 receiving a placebo [6] - Participants will receive nine doses over five days, with the first dose administered within 12 hours of injury [6] Medical Context - Mild TBI, or concussion, is a common form of head trauma with no FDA-approved drug therapies currently available, indicating a significant unmet medical need [4]